Orforglipron, Eli Lilly’s experimental weight-loss pill, achieved its primary goals during a carefully monitored late-stage study, which has helped the company to gain traction in a rapidly growing market for diabetes and obesity treatments.
Results announced on Thursday show that the pill may offer an attractive, non-needle alternative to injections. This could potentially change how millions of patients manage chronic diseases.
Investors welcomed Thursday’s results by boosting Eli Lilly shares up to 11%. This puts the company ahead of competitors such as Novo Nordisk, who are also working on an oral form of this lucrative GLP-1 drug class.
Orforglipron, a drug manufactured by the US-based pharmaceutical company Pfizer Inc., was reported to help patients with Type 2 Diabetes lose weight and improve their blood sugar levels.
This trial is one of seven studies in late stages that are underway. It also showed the side effects to be manageable, and similar to those observed with injectables already available on the market.
Alternatives to Injections
Orforglipron, at its maximum dose, caused an average loss in weight of 7.9% — or roughly 16 pounds over the course of 40 weeks.
The study found that patients’ weight loss had not plateaued by the time the trial was over, which suggests that a longer course of treatment could yield even better results.
The development of this product is important for those patients who are looking for a convenient and less expensive alternative to injectables such as Wegovy or Ozempic.
The manufacturing and distribution of pills at large scale is easier, helping to alleviate persistent shortages in the market that plague injectable GLP-1 drug.
In a statement, CEO David Ricks highlighted the possible impact.
It is pleasing to note that the latest incretin medication meets all of our requirements for weight loss, safety, tolerability and glucose control. “We look forward to receiving additional data later in the year.”
Expectations are met in terms of safety
Most side effects are mild or moderate. Gastrointestinal symptoms like nausea, vomiting and diarrhea were reported.
Analysts say that 8% of those who received the highest dosage discontinued their treatment because of side effects. This is within acceptable limits.
Comparatively, the discontinuation rate for injectables of this drug class is similar to or even slightly lower, despite their weekly administration rather than daily.
Analysts expected a discontinuation rate of around 9%. This means that results were close to expectations.
TD Cowen, along with other firms of investment, had predicted that the side effects would be slightly worse if you took a daily pill.
Results on Diabetes Metric are mixed
Orforglipron, although showing positive results, fell short of analyst expectations in lowering hemoglobin-A1c (a diabetes indicator).
After 40 weeks of taking the pill, blood sugar levels dropped from an initial level of 8 to between 1.3% and 1.6%.
The reduction in blood pressure was as high as 2,1% for some patients who used the injection Ozempic by Novo Nordisk.
This result is still clinically significant, but it could affect prescribing habits if doctors view insulin injections to be more effective in controlling glucose.
The ease of using the pill may still be sufficient to overcome patients’ preference for convenience.
Look ahead at regulatory filings
Eli Lilly intends to submit a regulatory application for orforglipron for obesity before the end of 2025. A diabetes submission is expected by 2026.
More data is expected in the coming months. The company currently conducts five diabetes trials and two obesity trials.
It is also not a drug based on peptides, so it can be absorbed by the body more readily and does not require dietary restrictions. Rybelsus, marketed by Novo Nordisk, is one such example.
It could be more attractive to a wider patient population.
By the early 2030s analysts predict that the GLP-1 drug market will exceed $150 billion, and oral medications could account for as much as $50 billion.
Orforglipron approval could cement Eli Lilly’s position as a market leader in injectable drugs such as Mounjaro.
Eli Lilly, with its competitive advantage over AstraZeneca and Roche as well as Structure Therapeutics and Viking Therapeutics is positioning itself for the launch of a GLP-1 oral therapy that will be widely available — reshaping the landscape in chronic disease management.
As new information becomes available, this post Eli Lilly stocks surge 11% after obesity pill succeeds in first late stage trial could be updated.
This site is for entertainment only. Click here to read more
